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Abstract The bacteriological efficacy response (improved,
arbekacin vs. vancomycin; 71.2% vs. 79.5%) and clinical
efficacy response (improved, arbekacin vs. vancomycin;
65.3% vs. 76.1%) were not statistically different between
the two groups. The complication rate was significantly
higher in the vancomycin group (32.9%) compared to the
arbekacin group (15.1%) (p=0.019). Arbekacin was not
inferior to vancomycin, and it could be a good alternative
drug for vancomycin in methicillin-resistant Staphylococcus
aureus (MRSA) treatment.
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is
frequently resistant to the majority of commonly used
antimicrobial agents, including beta-lactam antibiotics, ami-
noglycosides, macrolides, chloramphenicol, tetracycline, and
fluoroquinolones [1]. The prevalence of methicillin resis-
tance is known to be more than ~60–70% among S. aureus
isolates from hospitals in Korea [2, 3]. MRSA has become a
one of the most important causes of nosocomial pathogenic
infections, and the use of vancomycin for the treatment of
MRSA infection has increased [4]. Unfortunately,
vancomycin-resistant Enterococcus (VRE) and vancomycin-
resistant coagulase-negative Staphylococcus (VRCNS) have
been reported, as well as vancomycin-resistant S. aureus
(VRSA) [5–7]. To prevent the spread of VRE, VRCNS, and
VRSA, the use of vancomycin has to be reduced. This will
require the introduction of a new class of antibiotics that can
replace vancomycin [8].
Arbekacin is an antibacterial agent and belongs to the
aminoglycoside family of antibiotics. It was introduced to
treat MRSA infection. Pharmacokinetic advantages such as
concentration-dependant bactericidal activity and prolonged
post-antibiotic effect are more appreciable than vancomycin
[9]. However, only a few reports of clinical data describing
this new kind of antibiotic exist outside of Japan, which
was the first country that approved its use against MRSA
infections [10]. Therefore, presently, MRSA infection is
treated mainly with vancomycin and teicoplanin, which are
glycopeptide antibiotics.
We studied the clinical and bacteriological efficacy and
safety of arbekacin compared to vancomycin in the
treatment of infections caused by MRSA.
Method
This was a retrospective case–control study of patients who
were admitted to Chonbuk National University Hospital, a
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1,100-bed tertiary care university hospital in Jeonju, Korea,
from January 1st, 2009 to May 31st, 2010, and received the
antibiotics arbekacin or vancomycin. All of the MRSA-
infected patients who received arbekacin were enrolled
during the study period. The vancomycin group infected
by MRSA was selected by age and sex that matched the
arbekacin group. The study protocol was approved by
the Institutional Review Board of Chonbuk National
University Hospital.
In this study, nephrotoxicity was defined as when at least
50% reduction was seen in the glomerular filtration rate
(GFR) using the abbreviated modified diet in the renal disease
(MDRD) equation, which was GFR (mL/min/1.73 m2)=186
Pcr
−1.154 × age−0.203 × (1.212 if black) × (0.742 if female)
[11]. Hepatotoxicity was defined as when the aspartate
aminotransferase/alanine aminotransferase (ALT/AST) levels
were raised over two times the baseline values during
treatment. Leukocytopenia was defined as a continuous
decrease lower than 4.8 × 103/μL in the number of white
blood cells found in the complete blood cell count during
treatment. Drug fever was defined as a disorder characterized
by fever coinciding with the administration of a drug and
disappearing after the discontinuation of the drug [12].
The bacteriological efficacy response (BER) was classified
with improved and failure. The improved BERwas defined as
no growth of MRSA, whereas failure was defined as the
growth of MRSA culture at the end of therapy or during
treatment. The clinical efficacy response (CER) was classified
as improved and failure. Improved CER was defined as
resolution or reduction of the majority of signs and symptoms
related to the original infection. Failure was defined as no
resolution and no reduction of the majority of the signs and
symptoms, or the worsening of one or more signs and
symptoms, or new symptoms or signs associated with the
original infection or a new infection [13].
Categorical variables were compared by the Chi-squared
test and continuous variables were compared by the unpaired
t-test. SPSS software (version 15.0) was used throughout and
p-values of less than 0.05 were considered to be statistically
significant.
Table 1 General characteristics
of the study population
aOtitis media (13), meningitis
(6), pneumonia (29), peritonitis
(6), urinary tract infection
(UTI), cellulitis, neutropenic
fever (1)
Analyzed by the t-test and the
Chi-squared test
Arbekacin (n=73) Vancomycin (n=73) p-value
Age (years) 54.1±16.4 56.3±14.7 0.397
Sex
Male 43 (58.9%) 43 (58.9%) 1.000
Female 30 (41.1%) 30 (41.1%)
Department
Medical 15 (20.5%) 38 (52.1%) <0.001
Surgical 58 (79.5%) 35 (47.9%)
Clinical status
Sepsis 5 (6.8%) 6 (8.2%) 0.063
Wound- and catheter-related 45 (61.6%) 31 (42.5%)
Othersa 23 (31.5%) 36 (49.3%)
Medication duration (days) 19.4±15.7 18.2±11.3 0.608
Table 2 Safety and outcomes in
patients receiving arbekacin or
vancomycin




Analyzed by the Chi-squared
test
Arbekacin (n=73) Vancomycin (n=73) p-value
Complications
No 62 (84.9%) 49 (67.1%) 0.019
Yes 11 (15.1%) 24 (32.9%)
Nephrotoxicity 5 (6.8%) 6 (8.2%) 0.754
Leukopenia 4 (5.5%) 5 (6.8%) 0.731
Hepatotoxicity 3 (4.1%) 3 (4.1%) 1.000
Skin rash 0 (0.0%) 5 (6.8%) N/A
Drug fever 0 (0.0%) 6 (8.2%) N/A
Outcomes
BER Improved 52 (71.2%) 58 (79.5%) 0.249
Failure 21 (28.8%) 15 (20.5%)
CER Improved 47 (65.3%) 54 (76.1%) 0.157
Failure 25 (34.7%) 17 (23.9%)
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Results
A total of 146 patients were enrolled in this study. Seventy-
three patients receiving arbekacin were compared with the
same number of patients receiving vancomycin (Table 1).
The mean age of the arbekacin group was 54.1±16.4 years,
and that of the vancomycin group was 56.3±14.7 years.
There was no gender difference between the two groups.
The arbekacin group was more common in surgical section
than the vancomycin group (p<0.001). The clinical status
(p=0.063) or the medication duration (19.4±15.7 days vs.
18.2±11.3 days) was not different between the two groups.
The complications of the antibiotics between the two
groups were different (Table 2). The complication rate was
significantly higher in the vancomycin group (32.9%) than
in the arbekacin group (15.1%) (p=0.019). However,
individual complications such as nephrotoxicity, leukopenia,
and hepatotoxicity were not significantly different between
the two groups. Skin rash and drug fever occurred only among
patients in the vancomycin group. In the outcome section, the
BER (improved, arbekacin vs. vancomycin; 71.2% vs.
79.5%) and the CER (improved, arbekacin vs. vancomycin;
65.3% vs. 76.1%) were not statistically different between the
two groups (Table 2).
Discussion
In this study, arbekacin had a similar efficacy to vancomy-
cin in patients with MRSA. In addition, the side effects in
the arbekacin group were significantly lower than in the
vancomycin group. This showed that arbekacin may be a
good alternative drug for the treatment of infectious disease
with MRSA. Furthermore, this could lead to the decrease of
vancomycin usage in hospitals and decrease antibiotic-
resistant microorganisms, particularly VRE and vancomycin-
intermediate S. aureus (VISA), in clinical settings.
Approximately 80% of S. aureus strains isolated in
intensive care units (ICUs) are resistant to methicillin in
Asia [14]. More than 60% of MRSA were found in central
line-associated bloodstream infections in ICUs from the
United States [15]. Glycopeptides such as vancomycin and
teicoplanin are still the most frequently chosen antibiotics
for the treatment of MRSA infections, but the susceptibility
to vancomycin diminished in MRSA strains [16]. In
addition, VRSA strains have emerged in clinical settings
[17]. Although VRSA infections continue to be rare and no
transmission has been identified, it remains a serious public
health concern all over the world. It was shown that, with
more vancomycin exposure, there was a higher risk for
VRSA or VRE [17]. Prudent use of vancomycin as well as
the development of alternative therapeutic options against
MRSA is, therefore, required.
Arbekacin, a derivative of the aminoglycoside dibekacin,
has been reported to have good in vitro activity against
MRSA [18, 19]. Previous reports showed that the majority
of MRSA isolates in Europe and Japan were susceptible to
arbekacin [20]. Arbekacin has been used for the treatment
of MRSA infections is shown to be as useful as vancomycin
based on clinical data [21, 22]. Lee et al. showed that
arbekacin-based combination regimens could be an alternative
option for glycopeptides in the treatment of MRSA or hetero-
VISA infection [19]. In this study, arbekacin was not
different to vancomycin in clinical trials. This shows that
arbekacin could be a good alternative drug for glycopeptides.
The major side effects of vancomycin include local
phlebitis, fever, neutropenia, skin rash, and renal toxicity
[23]. The major side effects of arbekacin were renal and ear
toxicity, like other aminoglycosides [18]. In this study,
individual side effects of the antibiotics were not different
between the two groups. However, arbekacin had fewer
side effects than vancomycin overall.
There were several limitations in this study. First, it was
a retrospective case–control study. Second, the two groups
were not balanced at the clinical department. Surgical
patients had a higher representation in the arbekacin group.
However, the clinical status was not different between the
two groups.
In conclusion, arbekacin was not inferior to vancomycin.
We suggest that arbekacin could be a good alternative drug
for vancomycin in MRSA treatment in the hospital. More
well-designed studies are required in order to evaluate the
exact clinical response between arbekacin and vancomycin.
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